ACAD

Over the past six months, ACADIA's stock was significantly impacted on September 24, 2026, by a 12.78% drop after its Phase 2 RADIANT study for remlifanserin in Alzheimer's disease psychosis narrowly missed the primary endpoint, leading to further decline and analyst downgrades. On September 28, 2026, a U.S. patent covering weight-banded dosing of trofinetide was allowed, extending protections to March 2041. The company's second-quarter 2026 earnings exceeded expectations on August 4, 2026, causing a 6.08% stock price increase. In August 2026, EVP Mark C. Schneyer sold 14,292 shares, and State Street Corporation disclosed a 5.3% stake. In July 2026, EVP Elizabeth Thompson sold 16,558 shares. The stock also saw increases on June 26, 2026 (6.75%) and May 6, 2026 (5.03%). Overall, ACAD's stock trended down by 13.21% over the past six months.